YatzidisH.: A convenient hemoperfusion micro-apparatus over charcoal for the treatment of endogenous and exogenous intoxications.Its use as an effective artificial kidney. Proc. Eur. Dial. Transpl. Assoc.1, 83–87, 1964.
2.
AndradeJ.D., ColemanD.L., KimS.W., LentzD.J.: The coating of activated carbons for optimal blood compatability. In: Artificial Liver Support.WilliamsR., Murray-LyonI.M. eds. Pitman Medical, London pp. 84–94, 1975.
3.
WinchesterJ.F.: Hemostatic changes induced by adsorbent hemoperfusion. In: Artificial Organs.KenediR.M., CoutneyJ.M., GaylorJ.D.S., GilchristT. eds. Macmillan Press Ltd., London pp. 280–90, 1977.
4.
WinchesterJ.F., GelfandM.C.: Hemoperfusion in drug intoxication: clinical and laboratory aspects.Drug Metab. Res.8, 69–104, 1978.
5.
TonH.Y., HughesR.D., SilkD.B.A., WilliamsR.: Adsorption of human serum albumin to Amberlite XAD-7 resin.J. Biomed. Mat. Res.13, 407–422, 1979.
6.
DunlopE.H., HughesR.D., WilliamsR.: Physico-chemical aspects of the removal of protein bound substances by charcoal and other adsorbent of potential value in systems of artificial liver support.Part 1 Equilibrium properties. Med. Biol. Eng. Comput.16, 343–49, 1978.
7.
LangleyP.G., FennimoreJ., MunroG.D., HodgsonM.E.: The effect of coating on adsorption. In: Artificial Liver, Support.WilliamsR., Murray LyonI.M., eds. Pitman Medical, London, 337–43, 1975.
8.
HughesR.D., TonH.Y., LangleyP.G., SilkD.B.A., WilliamsR.: The use of an in vitro hemoperfusion circuit to evaluate the blood compatibility of albumin coated Amberlite XAD-7 resin.Int. J. Art. Org.1, 129–341978.
9.
GazzardB.G., LangleyP.G., WestonM.J., DunlopE.H., WilliamsR.: Polymer coating of activated charcoal and its effects on biocompatibility and paracetamol binding.Clin. sci. Mol. Med.47, 97–104, 1974.
10.
HughesR.D., TonH.Y., WilliamsR.: Adsorption studies on albumin-coated Amberlite XAD-7 for hemoperfusion in acute liver failuure.Proc. Eur. Soc. Art. Org.6, 297–300, 1979.
11.
DunlopE.H., LangleyP.G.: Column design for adsorbent systems and its effect on mass transfer. In: Artificial Liver Support.WilliamsR., Murray-LyonI.M., Eds. Pitman Medical, London pp. 310–318, 1975.
12.
DunlopE.H., GazzardB.G., LangleyP.G., WestonM.J., CoxL.R., WilliamsR.: Design features of hemoperfusion columns containing activated charcoal.Med. Biol. Eng.14, 220–26, 1976.
FennimoreJ., KolthammerJ.C., LangS.M.: Evaluation of hemoperfusion systems: in vitro methods related to performance and safety. In: Artificial Organs.KenediR.M., CourtneyJ.M., GaylorJ.D.S., GilchristT. eds. Macmillan Press Ltd, London pp. 148–157, 1977.
15.
NolanJ.P., McDevittJ.J., GoldmanG.S.: Endotoxin binding by charged and uncharged resins.Proc. Soc. Exp. Biol. Med.149, 766–770, 1975.
16.
GimsonA.E.S., LangleyP.G., HughesR.D., CanaleseJ., MellonP.J., WilliamsR., WoodsH.F., WestonM.J.: The use of prostacyclin to prevent platelet activation during charcoal hemoperfusion in fulminant hepatic failure.Lanceti, 173–75, 1980.